SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Epigral informs about financial results

28 Jan 2025 Evaluate
Epigral has informed that pursuant to SEBI Circular No. SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated 31st December, 2024, read with BSE Circular No. 20250102-4 and NSE Circular No. NSE/CML/2025/02 dated 2nd January, 2025, Integrated Filing (Financial) for the third quarter and nine months ended on 31st December, 2024 is enclosed.

The above information is a part of company’s filings submitted to BSE.

Epigral Share Price

1055.10 -57.25 (-5.15%)
11-Jun-2026 16:01 View Price Chart
Peers
Company Name CMP
SRF 2653.00
BASF India 3250.00
Tata Chemicals 741.00
Pidilite Inds. 1500.25
Deepak Nitrite 1611.15
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: